These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32238734)

  • 21. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures.
    Nishida Y; Kawaoka T; Imamura M; Namba M; Fujii Y; Uchikawa S; Ohya K; Daijo K; Teraoka Y; Morio K; Fujino H; Nakahara T; Yamauchi M; Hiramatsu A; Tsuge M; Aikata H; Takahashi S; Hayes CN; Fukuhara T; Tsuji K; Arataki K; Nagaoki Y; Aisaka Y; Kamada K; Kodama H; Chayama K
    Intern Med; 2021 Mar; 60(6):829-837. PubMed ID: 33087674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease.
    Yoshida M; Tateishi R; Hiroi S; Hongo Y; Fujiwara M; Kitanishi Y; Iwasaki K; Takeshima T; Igarashi A
    Adv Ther; 2022 Jan; 39(1):379-390. PubMed ID: 34748184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child-Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance.
    Flamm SL; Peck-Radosavljevic M; Fukuhara T; Bentley R; Katsube T; Ochiai T; Kano T; Tsukimura E; Sasaki R; Osaki Y
    Adv Ther; 2022 Sep; 39(9):4285-4298. PubMed ID: 35904722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease.
    Sano Y; Morimoto M; Kobayashi S; Ueno M; Fukushima T; Asama H; Kawano K; Nagashima S; Tanaka S; Ohkawa S; Maeda S
    Digestion; 2021; 102(4):654-662. PubMed ID: 32841939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bleeding events in lusutrombopag-treated thrombocytopenic patients.
    Giannini EG; Kano T; Ochiai T; Bentley R; Shrestha P; Afdhal N
    Eur J Clin Invest; 2021 Jun; 51(6):e13503. PubMed ID: 33523482
    [No Abstract]   [Full Text] [Related]  

  • 26. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
    Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
    J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient.
    Sakamaki A; Watanabe T; Abe S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
    Clin J Gastroenterol; 2017 Jun; 10(3):261-264. PubMed ID: 28324272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lusutrombopag as pretreatment for liver biopsy following liver transplantation.
    Katano T; Sanada Y; Okada N; Mizuta K
    Pediatr Int; 2018 Nov; 60(11):1033-1034. PubMed ID: 30375132
    [No Abstract]   [Full Text] [Related]  

  • 29. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.
    Ding Z; Wu H; Zeng Y; Kuang M; Yang W; Meng Z; Chen Y; Hao C; Zou S; Sun H; Liu C; Lin K; Shi G; Wang X; Fu X; Chen R; Chen Y; Liang R; Kano T; Pan H; Yang S; Fan J; Zhou J
    Hepatol Int; 2023 Feb; 17(1):180-189. PubMed ID: 36258065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
    Xu H; Cai R
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
    [No Abstract]   [Full Text] [Related]  

  • 31. A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series.
    Biolato M; Vitale F; Marrone G; Miele L; Grieco A
    Medicine (Baltimore); 2022 Nov; 101(44):e31429. PubMed ID: 36343065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lusutrombopag as a substitute for platelet transfusion for thrombocytopenia associated with chronic liver disease in a patient undergoing endoscopic spinal surgery: A case report.
    Kaneko T; Takano Y; Ishibashi K
    Medicine (Baltimore); 2021 Jan; 100(2):e24094. PubMed ID: 33466174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Avatrombopag: A Review in Thrombocytopenia.
    Markham A
    Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma.
    Alkhouri N; Imawari M; Izumi N; Osaki Y; Ochiai T; Kano T; Bentley R; Trevisani F
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2600-2608.e1. PubMed ID: 32205226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two cases of liver cirrhosis treated with lusutrombopag before partial splenic embolization.
    Fujita M; Abe K; Hayashi M; Okai K; Takahashi A; Ohira H
    Fukushima J Med Sci; 2017 Dec; 63(3):165-171. PubMed ID: 29142151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative systems pharmacology model of thrombopoiesis and platelet life-cycle, and its application to thrombocytopenia based on chronic liver disease.
    Shimizu R; Katsube T; Wajima T
    CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):489-499. PubMed ID: 33797208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study.
    Kawaratani H; Tsuji Y; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Sato S; Takaya H; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
    Hepatol Res; 2020 Sep; 50(9):1101-1105. PubMed ID: 32558192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia.
    Ishikawa T; Okoshi M; Tomiyoshi K; Kojima Y; Horigome R; Imai M; Nozawa Y; Iwanaga A; Sano T; Honma T; Yoshida T
    Hepatol Res; 2019 May; 49(5):590-593. PubMed ID: 30602063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study.
    Gallo P; De Vincentis A; Terracciani F; Falcomatà A; Pace Palitti V; Russello M; Vignone A; Alvaro D; Tortora R; Biolato M; Pompili M; Calvaruso V; Marzia V; Tizzani M; Caneglias A; Frigo F; Gesualdo M; Marzano A; Rosato V; Claar E; Villani R; Izzi A; Cozzolongo R; Cozzolino A; Airoldi A; Mazzarelli C; Distefano M; Iegri C; Fagiuoli S; Messina V; Ragone E; Sacco R; Cacciatore P; Masutti F; Crocé SL; Moretti A; Flagiello V; Di Pasquale G; Picardi A; Vespasiani-Gentilucci U
    J Clin Med; 2024 Jul; 13(13):. PubMed ID: 38999529
    [No Abstract]   [Full Text] [Related]  

  • 40. Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl.
    Yoshida H; Yamada H; Nogami W; Dohi K; Kurino-Yamada T; Sugiyama K; Takahashi K; Gahara Y; Kitaura M; Hasegawa M; Oshima I; Kuwabara K
    Exp Hematol; 2018 Mar; 59():30-39.e2. PubMed ID: 29274361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.